Carlos Arteaga

April 17, 2014

VICC’s Arteaga assumes presidency of AACR

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and Donna S. Hall Professor of Breast Cancer Research at Vanderbilt-Ingram Cancer Center (VICC), assumed the presidency of the American Association for Cancer Research (AACR) for 2014-2015 during the group’s annual meeting last week in San Diego.

By VUMC News and Communications
November 25, 2013

Vanderbilt celebrates 18 elected fellows of the AAAS

Eighteen academic and administrative leaders at Vanderbilt University have been elected fellows of the American Association for the Advancement of Science (AAAS) this year.

By Bill Snyder
November 7, 2013

Breast SPORE lands NCI renewal

Vanderbilt-Ingram Cancer Center’s Breast Specialized Program of Research Excellence (SPORE) has been awarded a third round of funding from the National Cancer Institute (NCI).

By VUMC News and Communications
October 31, 2013

VICC debuts new Center for Cancer Targeted Therapies

Vanderbilt-Ingram Cancer Center leaders formally dedicated the space for the new Center for Cancer Targeted Therapies (CCTT), located in the Infusion Center on the second floor of The Vanderbilt Clinic, at a special ribbon-cutting held during last week’s fall meeting of the Cancer Center’s Board of Overseers.

By VUMC News and Communications
August 15, 2013

Komen grants bolster breast cancer research

Vanderbilt-Ingram Cancer Center investigators are receiving $1 million in breast cancer research grant funds from Susan G. Komen, the largest nonprofit foundation supporting breast cancer research.

By VUMC News and Communications
May 9, 2013

Arteaga to lead major new cancer research initiatives

Carlos Arteaga, M.D., professor of Medicine and Cancer Biology, has been appointed to lead two newly created cancer research initiatives at the Vanderbilt-Ingram Cancer Center.

By VUMC News and Communications
April 4, 2013

VU’s Arteaga to lead American Association for Cancer Research

Carlos Arteaga, M.D., professor of Medicine and Cancer Biology at Vanderbilt, has been elected president-elect of the American Association for Cancer Research for 2013-2014.
By VUMC News and Communications
March 21, 2013

Breast cancer study explores therapy to slow recurrence

Many patients with triple-negative breast cancer (TNBC) have recurrence of their disease after an initial response to chemotherapy because the cancer cells have become resistant to treatment. TNBC has a lower survival rate because of this pattern of resistance and there are no targeted agents to treat this form of breast cancer.
By VUMC News and Communications
December 7, 2012

Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.
By VUMC News and Communications
August 30, 2012

Stand Up to Cancer TV broadcast airs Sept. 7

By VUMC News and Communications
August 2, 2012

Arteaga named to Komen scientific advisory board

Carlos Arteaga, M.D., associate director for Clinical Research and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named to the Scientific Advisory Board of the Susan G. Komen for the Cure Breast Cancer Research Foundation.
By VUMC News and Communications
June 11, 2012

Vanderbilt identifies genes linked to breast cancer chemo resistance

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer.
By VUMC News and Communications
1 2 3